Ontology type: schema:ScholarlyArticle
2014-10-11
AUTHORSR. R. Recker, L.-G. Ste-Marie, P. Chavassieux, M. R. McClung, M. W. Lundy
ABSTRACTThis report describes bone safety and histomorphometric data across different dose levels and dosing frequencies of risedronate. Normal bone structure and histomorphometric data were observed, with ongoing bone remodeling and mineralization regardless of dose. These data are reassuring and do not suggest compromised bone remodeling during treatment with established risedronate regimens.IntroductionThe efficacy and bone safety of risedronate 5 mg daily were established in pivotal phase III randomized, placebo-controlled clinical studies. Histomorphometric analysis of paired biopsies demonstrated bone safety as reflected by presence of fluorescent tetracycline double-labels in all evaluable biopsies. This report describes bone safety and histomorphometric data across studies of various dose regimens of risedronate.MethodsBridging studies, with bone mineral density as the primary endpoint, demonstrated non-inferiority of risedronate 35 mg and 50 mg once a week, risedronate 150 mg once a month, and a risedronate 75-mg dose on two consecutive days a month versus risedronate 5 mg daily. The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35 mg to be taken weekly, before or after breakfast. Bone biopsies were collected at 24 months in studies involving these risedronate dosing regimens; bone safety and histomorphometric data were evaluated.ResultsQualitative bone histology showed normal mineralization of newly formed bone without evidence of pathological findings, such as osteomalacia, bone marrow dyscrasia, or bone marrow fibrosis. Importantly, ongoing bone remodeling, based on fluorochrome labeling, was observed in all patients regardless of dose and exposure. Key histomorphometric variables were comparable to those observed with the risedronate 5 mg daily dose and were within the range seen in healthy pre- and post-menopausal women.ConclusionsOverall, the results are reassuring with respect to bone safety and histomorphometric data, and do not suggest oversuppression of bone remodeling during treatment with these established risedronate regimens. More... »
PAGES327-337
http://scigraph.springernature.com/pub.10.1007/s00198-014-2850-y
DOIhttp://dx.doi.org/10.1007/s00198-014-2850-y
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1044416054
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/25304456
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Biopsy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Density Conservation Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone Remodeling",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bone and Bones",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Clinical Trials, Phase III as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Dose-Response Relationship, Drug",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Double-Blind Method",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Etidronic Acid",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Multicenter Studies as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Osteoporosis, Postmenopausal",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Randomized Controlled Trials as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risedronic Acid",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Osteoporosis Research Center, Creighton University School of Medicine, 601 N. 30th Street Suite 4820, 68131, Omaha, NE, USA",
"id": "http://www.grid.ac/institutes/grid.254748.8",
"name": [
"Osteoporosis Research Center, Creighton University School of Medicine, 601 N. 30th Street Suite 4820, 68131, Omaha, NE, USA"
],
"type": "Organization"
},
"familyName": "Recker",
"givenName": "R. R.",
"id": "sg:person.016325222544.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universit\u00e9 de Montr\u00e9al, CHUM H\u00f4pital Saint-Luc, Montr\u00e9al, QC, Canada",
"id": "http://www.grid.ac/institutes/grid.414407.2",
"name": [
"Universit\u00e9 de Montr\u00e9al, CHUM H\u00f4pital Saint-Luc, Montr\u00e9al, QC, Canada"
],
"type": "Organization"
},
"familyName": "Ste-Marie",
"givenName": "L.-G.",
"id": "sg:person.0604422400.96",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604422400.96"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "INSERM U1033, Universit\u00e9 de Lyon, Lyon, France",
"id": "http://www.grid.ac/institutes/grid.25697.3f",
"name": [
"INSERM U1033, Universit\u00e9 de Lyon, Lyon, France"
],
"type": "Organization"
},
"familyName": "Chavassieux",
"givenName": "P.",
"id": "sg:person.0736114273.18",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736114273.18"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Oregon Osteoporosis Center, Portland, OR, USA",
"id": "http://www.grid.ac/institutes/grid.240531.1",
"name": [
"Oregon Osteoporosis Center, Portland, OR, USA"
],
"type": "Organization"
},
"familyName": "McClung",
"givenName": "M. R.",
"id": "sg:person.01202365465.00",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202365465.00"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA",
"id": "http://www.grid.ac/institutes/grid.257413.6",
"name": [
"Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN, USA"
],
"type": "Organization"
},
"familyName": "Lundy",
"givenName": "M. W.",
"id": "sg:person.01222544011.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222544011.08"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00198-012-2056-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035221448",
"https://doi.org/10.1007/s00198-012-2056-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-003-1530-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1045100855",
"https://doi.org/10.1007/s00198-003-1530-0"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-003-5001-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1017778946",
"https://doi.org/10.1007/s00223-003-5001-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-011-1791-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040344660",
"https://doi.org/10.1007/s00198-011-1791-y"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf02058664",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1002104346",
"https://doi.org/10.1007/bf02058664"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00198-003-1466-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000235901",
"https://doi.org/10.1007/s00198-003-1466-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s11926-003-0085-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1019453140",
"https://doi.org/10.1007/s11926-003-0085-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-004-0039-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046491481",
"https://doi.org/10.1007/s00223-004-0039-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s001980050010",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005303812",
"https://doi.org/10.1007/s001980050010"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00223-012-9668-4",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023163828",
"https://doi.org/10.1007/s00223-012-9668-4"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf02196199",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1018222560",
"https://doi.org/10.1007/bf02196199"
],
"type": "CreativeWork"
}
],
"datePublished": "2014-10-11",
"datePublishedReg": "2014-10-11",
"description": "This report describes bone safety and histomorphometric data across different dose levels and dosing frequencies of risedronate. Normal bone structure and histomorphometric data were observed, with ongoing bone remodeling and mineralization regardless of dose. These data are reassuring and do not suggest compromised bone remodeling during treatment with established risedronate regimens.IntroductionThe efficacy and bone safety of risedronate 5\u00a0mg daily were established in pivotal phase III randomized, placebo-controlled clinical studies. Histomorphometric analysis of paired biopsies demonstrated bone safety as reflected by presence of fluorescent tetracycline double-labels in all evaluable biopsies. This report describes bone safety and histomorphometric data across studies of various dose regimens of risedronate.MethodsBridging studies, with bone mineral density as the primary endpoint, demonstrated non-inferiority of risedronate 35\u00a0mg and 50\u00a0mg once a week, risedronate 150\u00a0mg once a month, and a risedronate 75-mg dose on two consecutive days a month versus risedronate 5\u00a0mg daily. The low oral bioavailability and known dosing limitations due to food interactions of bisphosphonates have led to development of an oral delayed-release dose form of risedronate 35\u00a0mg to be taken weekly, before or after breakfast. Bone biopsies were collected at 24\u00a0months in studies involving these risedronate dosing regimens; bone safety and histomorphometric data were evaluated.ResultsQualitative bone histology showed normal mineralization of newly formed bone without evidence of pathological findings, such as osteomalacia, bone marrow dyscrasia, or bone marrow fibrosis. Importantly, ongoing bone remodeling, based on fluorochrome labeling, was observed in all patients regardless of dose and exposure. Key histomorphometric variables were comparable to those observed with the risedronate 5\u00a0mg daily dose and were within the range seen in healthy pre- and post-menopausal women.ConclusionsOverall, the results are reassuring with respect to bone safety and histomorphometric data, and do not suggest oversuppression of bone remodeling during treatment with these established risedronate regimens.",
"genre": "article",
"id": "sg:pub.10.1007/s00198-014-2850-y",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1100834",
"issn": [
"0937-941X",
"1433-2965"
],
"name": "Osteoporosis International",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "26"
}
],
"keywords": [
"bone safety",
"risedronate 5",
"histomorphometric data",
"different dose levels",
"risedronate 35",
"dose levels",
"placebo-controlled clinical study",
"bone remodeling",
"phase III randomized",
"post-menopausal women",
"bone marrow fibrosis",
"bone mineral density",
"bone marrow dyscrasia",
"ongoing bone remodeling",
"normal bone structure",
"low oral bioavailability",
"IntroductionThe efficacy",
"evaluable biopsies",
"primary endpoint",
"healthy pre",
"dose regimens",
"daily dose",
"pathological findings",
"marrow fibrosis",
"bone biopsy",
"mineral density",
"clinical studies",
"histomorphometric study",
"regimens",
"food interactions",
"histomorphometric analysis",
"normal mineralization",
"consecutive days",
"biopsy",
"oral bioavailability",
"risedronate",
"dose",
"histomorphometric variables",
"bone histology",
"fluorochrome labeling",
"dose forms",
"months",
"bone structure",
"bone",
"safety",
"remodeling",
"treatment",
"exposure",
"report",
"oversuppression",
"Randomized",
"osteomalacia",
"patients",
"bisphosphonates",
"dyscrasias",
"fibrosis",
"histology",
"study",
"breakfast",
"endpoint",
"weeks",
"women",
"efficacy",
"levels",
"ConclusionsOverall",
"tetracycline",
"days",
"pre",
"bioavailability",
"data",
"findings",
"evidence",
"labeling",
"presence",
"frequency",
"development",
"variables",
"analysis",
"results",
"limitations",
"form",
"mineralization",
"interaction",
"respect",
"range",
"density",
"structure"
],
"name": "Bone safety with risedronate: histomorphometric studies at different dose levels and exposure",
"pagination": "327-337",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1044416054"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00198-014-2850-y"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"25304456"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00198-014-2850-y",
"https://app.dimensions.ai/details/publication/pub.1044416054"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:01",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_631.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00198-014-2850-y"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-014-2850-y'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-014-2850-y'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-014-2850-y'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-014-2850-y'
This table displays all metadata directly associated to this object as RDF triples.
304 TRIPLES
21 PREDICATES
141 URIs
122 LITERALS
25 BLANK NODES